Director/PDMR Shareholding
Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
The interest of David Brennan, a Director of the Company, in AstraZeneca PLC Ordinary Shares of $0.25 each, has changed as detailed below.
On 25 February 2011, Mr Brennan received shares from the vesting of a previously announced award made in February 2008 under the AstraZeneca Deferred Bonus Plan whereby he has now become beneficially entitled to the shares. Sufficient shares were withheld to cover certain tax obligations arising on the vesting.
|
Name of Director |
Number of shares vested |
Number of shares withheld |
Net number of shares |
Market price on vesting |
|
David R Brennan |
16,810 |
8,597 |
8,213 |
2945p |
On 25 February 2011, Mr Brennan was also allocated 17,725 shares under the previously disclosed arrangements relating to the payment of annual bonuses whereby he is required to defer a portion of the bonus earned into shares for a period of three years. The shares were allocated at a price of 2977 pence per share. Mr Brennan will become beneficially entitled to these shares on 25 February 2014.
Mr Brennan has interests in both the Ordinary Shares and the American Depositary Shares (ADSs) of AstraZeneca PLC. One ADS equals one Ordinary Share.
As a result of these transactions, Mr Brennan has an interest in 616,827 Ordinary Shares and 78,469 AstraZeneca ADSs, which together represent approximately 0.05% of the Company's issued ordinary capital.
A C N Kemp
Company Secretary
28 February 2011
This information is provided by RNS